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Abstract 
 
Objective: To evaluate effect of second hydrodistension on symptoms of patients who have diagnosed interstitial 
cystitis and have been performed hydrodistension before. Material-Methods: Data of the patients who have 
diagnosed interstitial cystitis and were performed hydrodistension between June 2015 and June 2017 were 
retrospectively evaluated. Diagnosis of interstitial cystitis was done on three criteria according to clinical guidelines. 
Hydrodistension was performed by a single surgeon under spinal anesthesia. The bladder was distended with normal 
saline through a cystoscope to provide pressure of 80 cmH2O. After hydrodistension for 5 minutes the bladder was 
evacuated, which might lead to hemorrhage of the apparently normal bladder mucosa (glomerulations). O’Leary–
Sant’s symptom and problem index (OS combined), Pelvic Pain and Urgency/Frequency (PUF) Patient Symptom 
Scale and the Likert visual analog scale (VAS) for pain were used to evaluate the severity of symptoms. After the 
hydrodistension, patients were followed-up by without medication. Second hydrodistension was performed when 
symptoms were recurred.   Results: Total 17 patients were diagnosed interstitial cystitis. Symptoms of seven 
patients were not improved by first hydrodistension, so second hydrodistension was not performed to these patients. 
These seven patients were excluded. Total 10 patients were included the study. Median OS combined (24 vs 20.5 p= 
0.356), PUF (33 vs 29 p= 0.113) and VAS (8 vs 7 p= 0.452) score were similar before and after second 
hydrodistension.  Conclusions: Second hydrodistension is not effective in interstitial cystitis patients whom were 
treated hydrodistension before. 
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Introduction 
 
Interstitial cystitis (IC) is achronic disease of unknown 
etiology characterized by persistent irritating 
micturition symptoms and pain [1]. Etiological factors 
may include urine-borne toxic substances, autoimmune 
disorders, a defect in the protective bladder’s mucous 
lining of glycosamino glycans (urine–tissue barrier), 
neurogenic inflammation, and C-fiber activation [2,3]. 
Treatment options are that behavioral modifications, 
pelvic floor muscle exercise, oral agents, intravesical 
instillation, and neuromodulation[4]. Bumpus reported 
hydrodistension (HD) outcomes firstly in 1930 [5]. The 
effectivity of HD is nearly 50% for analgesia [6]. 
However, this effect sustains only six months [7].  
We aimed to evaluate effect of second HD on 
symptoms of patients who have diagnosed IC and have 
been performed HD before.  
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Material & Methods 
Data of the patients who have diagnosed IC and were 
performed HD between June 2015 and June 2017 were 
retrospectively evaluated. Diagnosis of IC was done on 
three criteria according to clinical guidelines [8], these 
criteria are lower urinary tract symptoms, frequency, 
hypersensitivity, or pubic perineal pain and exclusion 
of other diseases with similar symptoms. 
Glomerulations after HD in the absence of Hunner 
lesions (non-Hunner type IC) was included, presence 
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of Hunner lesions was not included the study. Patients 
who did not benefit from the initial procedure or 
received intravesical treatment and have chronic 
disease (Sjögren’s syndrome, rheumatoid arthritis etc.) 
which related with IC were excluded. HD was 
performed by a single surgeon under spinal anesthesia. 
The bladder was distended with normal saline through 
a cystoscope to provide pressure of 80 cmH2O. After 
HD for 5 minutes the bladder was evacuated, which 
might lead to hemorrhage of the apparently normal 
bladder mucosa (glomerulations). O’Leary–Sant’s 
symptom and problemindex (OSSI), Pelvic Pain and 
Urgency/Frequency (PUF) Patient Symptom Scale and 
the Likert visual analog scale (VAS) for pain were used 
to evaluate the severity of symptoms. After the HD, 
patients were followed-up by without medication. Only 
non-steroid or narcotic analgesic were prescribed for 
on-demand. Second HD was performed when 
symptoms were recurred.   
Patients age, body-mass index, interval of between two 
HD procedures, OSSI, OSPI, PUF and VAS scores 
were recorded. Mann-Whitney U test was used for 
statistical analyze. SPSS package software 17 for 
windows (Chicago, Il) was used.  
All procedures were conducted in accordance 
with the ethical standards of the institutional and/or 
national research committees and with the 1964 
Helsinki Declaration and its later amendments or with 
comparable ethical standards. The authors conformed 
ethic rules of Committee on Publication Ethics and the 
International Committee of Medical Journal Editors. 
Human Research Ethics Committee and Institutional 
Review Board approvals and informed consent was not 
obtained due to retrospective nature. 
Results 
Total 17 patients were diagnosed IC. Symptoms of 
seven patients were not improved by first HD, so 
second HD was not performed to these patients. Total 
10 patients were included the study. Median age was 
58 (48-62) and body-mass index 29 (27-35).  The 
median time to therapeutic failure after first HD was 
six months (3-9 months). Effect of first and second HD 
on symptom scores are seen table-1. Each patient’s OS 
combined and PUF scores changing are shown figure 1 
and 2. No major complication was seen on any patient. 
Urinary tract infection was seen on three patients after 
first HD and three patients after second HD; all of 
patients were treated with just oral antibiotics.  
Table 1: Patients’ outcomes 
 Before First HD After First 
HD 
P value Before 
Second HD 
After Second HD P value 
OS Score 26 (15-36) 8.5(3-15) 0.005 24 (14-36) 20.5 (12—36) 0.356 
PUF Score 33.5 (24-45) 8 (2-12) <0.001 33 (28-40) 29 (24-40) 0.113 
VAS Score 8 (6-10) 2 (0-5) <0.001 8 (6-10) 7 (5-10) 0.452 
 
 
Figure 1: O’Leary-Sant combined symptom index and problem index scores 
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Figure 2: Pelvic Pain and Urgency Frequency combined symptom scores 
 
Discussion 
HD is one of the treatment choice for IC[8]. The 
mechanism of HD efficacy is not clear [9]. In the rat-
based study, induced ischemia of the bladder may 
cause relation of neuroproliferative factors, that 
suggesting that the restoration of damaged nerve 
endings [10]. In the clinical-based study, HD has 
limited persistence of efficacy, and initial response 
sustained in about a half of patients [11]. In the study, 
first HD improved 10 of 17 patients. We excluded 7 
patients whom symptoms were not improved by HD. 
After first HD, we have not given any oral or 
intravesical treatment, because any approved treatment 
option was not present in the city which these patients 
live until 2017. In this reason, we had to do second HD 
when symptoms recurred.  
Pain is nociceptive of chronic inflammation and 
neuropathic pain activated by afferent nerves 
innervating the bladder in IC patients [2,12]. Twenty-
seven percent of the patients with IC have neuropathic 
pain [13]. By a hypothesis, chronic bladder 
inflammation may cause to increase number of 
inflammation-related proteins/receptors, and this 
phenomenon induce afferent neuroplasticity that 
responsible for pain [14]. We think inflammation in IC 
is progressive process. First HD may do consolidate or 
delay inflammation by restoration of nerve-ending. 
Same effect could not achieve by second HD. Because, 
chronic inflammation process has continued. For this 
reason, HD might be first option as not only diagnostic 
but also treatment option for first stage, but after 
symptoms recurrence second HD is not treatment 
option.  
Small number of patients may be limit of the study. 
More significant results may achieve with more 
numbers of patients. Retrospective nature may seem 
lack of study, but prospective design may cause 
subjective results. This is first study which investigated 
second HD effect. 
Conclusions 
Second HD is not effective in IC patients whom were 
treated HD before. Oral or intravesical treatments 
should be considered for these patients whom 
symptoms were recurred after first HD. 
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